Science and Research

Burden of non-tuberculous mycobacterial pulmonary disease in Germany

The objective of this study was to estimate the burden of disease in incident patients with non-tuberculous mycobacterial pulmonary disease (NTM-PD).A sample of 7 073 357 anonymised persons covered by German public statutory health insurances was used to identify patients with NTM-PD. In total, 125 patients with newly diagnosed NTM-PD in 2010 and 2011 were matched with 1250 control patients by age, sex and Charlson Comorbidity Index, and followed for 39 months.The incidence rate for NTM-PD was 2.6 per 100 000 insured persons (95% CI 2.2-3.1). The mortality rate for patients with NTM-PD and the control group in the observational period was 22.4% and 6%, respectively (p<0.001). Mean direct expenditure per NTM-PD patient was euro39 559.60 (95% CI 26 916.49-52 202.71), nearly 4-fold (3.95, 95% CI 3.73-4.19) that for a matched control (euro10 006.71, 95% CI 8907.24-11 106.17). Hospitalisations were three times higher in the NTM-PD group and accounted for 63% of the total costs. Attributable annual direct costs and indirect work-loss costs in NTM-PD patients were euro9093.20 and euro1221.05 per control patient, respectively. Only 74% of NTM-PD patients received antibiotics and nearly 12% were prescribed macrolide monotherapy.Although NTM-PD is considered rare, the attributable mortality and financial burden in Germany are high. Efforts to heighten awareness of appropriate therapy are urgently needed.
  • Diel, R.
  • Jacob, J.
  • Lampenius, N.
  • Loebinger, M.
  • Nienhaus, A.
  • Rabe, K. F.
  • Ringshausen, F. C.

Keywords

  • Anti-Bacterial Agents/therapeutic use
  • Case-Control Studies
  • *Cost of Illness
  • Female
  • Germany/epidemiology
  • Health Care Costs
  • Hospitalization/statistics & numerical data
  • Humans
  • Insurance Claim Review
  • Kaplan-Meier Estimate
  • Lung Diseases/*drug therapy/*economics/microbiology/*mortality
  • Macrolides/therapeutic use
  • Male
  • Middle Aged
  • Mycobacterium Infections, Nontuberculous/*drug therapy/*economics/*mortality
  • Nontuberculous Mycobacteria/isolation & purification
  • Proportional Hazards Models
  • erj.ersjournals.com
Publication details
DOI: 10.1183/13993003.02109-2016
Journal: The European respiratory journal
Number: 4
Work Type: Original
Location: Assoziierter Partner, ARCN, BREATH
Disease Area: General Lung and Other
Partner / Member: Ghd, UKSH (Kiel)
Access-Number: 28446559
See publication on PubMed

DZL Engagements

chevron-down